Cancer Family
Anaplastic Malignant Neoplasm
CI-CAN-00000065Explore in graph →
546 active trials4 approved drugs57 evidence items
- NCIt
- C36025
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000065Explore in graph →
Clinical trials
2,019 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (323)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01576666 | Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors | completed | Phase 1 | 120 | Novartis PharmaceuticalsINDUSTRY | 8 | Dec 19, 2020 | clinicaltrials |
| NCT04674527 | Pilot Study of Elemene in Treating Patients With Refractory Glioblastoma | unknown | Phase 2 | 30 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Dec 19, 2020 | clinicaltrials |
| NCT04674579 | Automatic Segmentation MRI Cerebral Glioma | unknown | — | 50 | Assiut UniversityOTHER | 0 | Dec 19, 2020 | clinicaltrials |
| NCT02605746 | Preoperative Ceritinib (LDK378) in Glioblastoma Multiforme and CNS Metastasis | completed | Early Phase 1 | 10 | St. Joseph's Hospital and Medical Center, PhoenixOTHER | 1 | Dec 11, 2020 | clinicaltrials |
| NCT01905228 | A Phase 1 Trial of CBL0137 in Patients With Metastatic or Unresectable Advanced Solid Neoplasm | completed | Phase 1 | 83 | IncuronINDUSTRY | 1 | Dec 10, 2020 | clinicaltrials |
| NCT02207010 | A Phase 0 Study of AZD1775 in Recurrent GBM Patients | completed | Early Phase 1 | 20 | St. Joseph's Hospital and Medical Center, PhoenixOTHER | 1 | Dec 10, 2020 | clinicaltrials |
| NCT03353896 | NovoTTF-200A Device in Treating Patients With Newly Diagnosed High Risk Oligodendroglioma | withdrawn | N/A | 0 | University of Southern CaliforniaOTHER | 1 | Dec 10, 2020 | clinicaltrials |
| NCT01473901 | A Phase I Dose Escalation Study of BKM120 With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma | completed | Phase 1 | 38 | Novartis PharmaceuticalsINDUSTRY | 4 | Dec 9, 2020 | clinicaltrials |
| NCT01934361 | Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme | completed | Phase 1 | 35 | Novartis PharmaceuticalsINDUSTRY | 6 | Dec 9, 2020 | clinicaltrials |
| NCT03603379 | Doxorubicin-loaded Anti-EGFR-immunoliposomes (C225-ILs-dox) in High-grade Gliomas(GBM-LIPO) | completed | Phase 1 | 9 | University Hospital, Basel, SwitzerlandOTHER | 1 | Dec 8, 2020 | clinicaltrials |
| NCT03896958 | The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)(PIONEER) | unknown | — | 1,000 | SpeciCareINDUSTRY | 1 | Dec 4, 2020 | clinicaltrials |
| NCT04583020 | Neoadjuvant PD-1 in Newly Diagnosed Glioblastoma | unknown | Phase 2 | 42 | Peking Union Medical College HospitalOTHER | 1 | Nov 30, 2020 | clinicaltrials |
| NCT00031083 | Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the Treatment of Grade III & Grade IV Gliomas | completed | Phase 1 | 12 | BiogenINDUSTRY | 1 | Nov 17, 2020 | clinicaltrials |
| NCT03619239 | Dose-escalation Study to Evaluate the Safety and Tolerability of GX-I7 in Patients With Glioblastoma(GBM) | completed | Phase 1 | 15 | Genexine, Inc.INDUSTRY | 1 | Nov 10, 2020 | clinicaltrials |
| NCT01943682 | Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma | completed | Phase 1 | 27 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Nov 9, 2020 | clinicaltrials |
| NCT01258998 | Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma | completed | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Nov 4, 2020 | clinicaltrials |
| NCT00052208 | Gefitinib and Radiation Therapy in Treating Patients With Glioblastoma Multiforme | completed | Phase 1 / Phase 2 | 158 | National Cancer Institute (NCI)NIH | 1 | Oct 30, 2020 | clinicaltrials |
| NCT01075321 | Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 58 | Mayo ClinicOTHER | 1 | Oct 22, 2020 | clinicaltrials |
| NCT04270461 | NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors | withdrawn | Phase 1 | 0 | Jiujiang University Affiliated HospitalOTHER_GOV | 1 | Oct 22, 2020 | clinicaltrials |
| NCT02709889 | Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 200 | AbbVieINDUSTRY | 1 | Oct 19, 2020 | clinicaltrials |
| NCT03903419 | Feasibility Study of 68Ga-PSMA PET-CT and 18F-FDOPA PET-CT in Glioblastoma's Patients(PAraDiGM) | unknown | N/A | 16 | Centre Leon BerardOTHER | 1 | Oct 14, 2020 | clinicaltrials |
| NCT03463733 | Hydroxy-urea and Temozolomide in Patients With a Recurrent Malignant Brain Tumor (Glioblastoma)(HUTMZ) | unknown | Phase 1 | 54 | M.E. van LindeOTHER | 1 | Oct 8, 2020 | clinicaltrials |
| NCT03151772 | Bioavailability of Disulfiram and Metformin in Glioblastomas(INSIDE) | terminated | Early Phase 1 | 3 | Sahlgrenska University HospitalOTHER | 1 | Sep 28, 2020 | clinicaltrials |
| NCT02029690 | Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin(TRAP) | terminated | Phase 1 | 85 | Polaris GroupINDUSTRY | 2 | Sep 25, 2020 | clinicaltrials |
| NCT00586508 | Trial of Enzastaurin and Bevacizumab in Participants With Recurrent Malignant Gliomas | completed | Phase 2 | 81 | Eli Lilly and CompanyINDUSTRY | 1 | Sep 24, 2020 | clinicaltrials |
| NCT00050986 | Phase I/II Evaluation of Temozolomide and ZARNESTRA (R115777) for Recurrent and Progressive Glioblastoma Multiforme | completed | Phase 1 / Phase 2 | 55 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 22, 2020 | clinicaltrials |
| NCT04552977 | A Trail of Fluzoparil in Combination With Temozolomide in Patients With Recurrent Glioblastoma | unknown | Phase 2 | 50 | Shandong Cancer Hospital and InstituteOTHER | 0 | Sep 17, 2020 | clinicaltrials |
| NCT04547855 | Anlotinib Combined With Dose-dense Temozolomide for the First Recurrent or Progressive Glioblastoma After STUPP Regimen | unknown | Phase 2 | 54 | Yonggao MouOTHER | 1 | Sep 14, 2020 | clinicaltrials |
| NCT01567202 | Study of DC Vaccination Against Glioblastoma | unknown | Phase 2 | 100 | Huashan HospitalOTHER | 1 | Sep 9, 2020 | clinicaltrials |
| NCT03506139 | Biologically-based Target Volumes to Treat Newly Diagnosed Glioblastoma | withdrawn | Phase 2 | 0 | John M. BuattiOTHER | 1 | Sep 9, 2020 | clinicaltrials |
| NCT01987830 | Bevacizumab w / Temozolomide PET & Vascular MRI For GBM | completed | N/A | 13 | Massachusetts General HospitalOTHER | 1 | Sep 4, 2020 | clinicaltrials |
| NCT02590263 | Study Evaluating ABT-414 in Japanese Subjects With Malignant Glioma | completed | Phase 1 / Phase 2 | 53 | AbbVieINDUSTRY | 1 | Sep 3, 2020 | clinicaltrials |
| NCT04536649 | Proton and Heavy Ion Beam Radiation vs. Photon Beam Radiation for Newly Diagnosed Glioblastoma. | unknown | Phase 3 | 369 | Shanghai Proton and Heavy Ion CenterOTHER | 1 | Sep 2, 2020 | clinicaltrials |
| NCT00402116 | Phase 1/2 Study of Enzastaurin in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients | completed | Phase 1 / Phase 2 | 72 | Eli Lilly and CompanyINDUSTRY | 1 | Aug 6, 2020 | clinicaltrials |
| NCT00179803 | Stem Cell Transplant for High Risk Central Nervous System (CNS) Tumors | completed | Phase 2 | 24 | Ann & Robert H Lurie Children's Hospital of ChicagoOTHER | 1 | Aug 5, 2020 | clinicaltrials |
| NCT04488783 | Potentiation of Chemotherapy in Brain Tumors by Zinc | unknown | N/A | 30 | Sheba Medical CenterOTHER_GOV | 1 | Jul 28, 2020 | clinicaltrials |
| NCT01813877 | Response Monitoring Trial in Patients With Suspected Recurrence of Glioblastoma | completed | N/A | 37 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 27, 2020 | clinicaltrials |
| NCT02919332 | Delayed 18F-FDG PET/CT in Improving Visualization of Brain Tumors in Patients With Glioblastoma | withdrawn | — | 0 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 24, 2020 | clinicaltrials |
| NCT03014804 | Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma | withdrawn | Phase 2 | 0 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 24, 2020 | clinicaltrials |
| NCT00943462 | Study of 18F-FEC for Positron Emission Tomography-Computed Tomography (PET-CT) Imaging of GBM | withdrawn | — | 0 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 0 | Jul 23, 2020 | clinicaltrials |
| NCT03734913 | A Phase 1 Study of ZSP1602 in Participants With Advanced Solid Tumors | unknown | Phase 1 | 65 | Guangdong Zhongsheng Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 22, 2020 | clinicaltrials |
| NCT02626364 | Study of Crenolanib in Recurrent/Refractory Glioblastoma With PDGFRA Gene Amplification | completed | Phase 2 | 11 | Arog Pharmaceuticals, Inc.INDUSTRY | 1 | Jul 20, 2020 | clinicaltrials |
| NCT03687099 | Immunological and Functional Characterization of Cellular Population CD45+ Infiltrating Human Glioblastoma(GLIOBLASTOMES) | completed | — | 20 | Centre Hospitalier Universitaire, AmiensOTHER | 1 | Jul 16, 2020 | clinicaltrials |
| NCT03115138 | Evaluation of Circulating Tumor DNA as a Theranostic Marker in the Management of Glioblastomas.(Bi-GLAM) | terminated | N/A | 19 | Centre Hospitalier Universitaire, AmiensOTHER | 1 | Jul 15, 2020 | clinicaltrials |
| NCT03707457 | Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of Glioblastoma | terminated | Phase 1 | 3 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jul 2, 2020 | clinicaltrials |
| NCT01790503 | A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma | completed | Phase 1 / Phase 2 | 65 | Daiichi SankyoINDUSTRY | 1 | Jun 30, 2020 | clinicaltrials |
| NCT04450160 | Trial of AEO in New Glioblastoma (GBM)(AEO) | unknown | Phase 2 | 80 | MetVital, Inc.INDUSTRY | 0 | Jun 29, 2020 | clinicaltrials |
| NCT01349660 | Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme | completed | Phase 1 / Phase 2 | 88 | SCRI Development Innovations, LLCOTHER | 1 | Jun 17, 2020 | clinicaltrials |
| NCT03231501 | HMPL-813 in Treating Patients With Glioblastoma | unknown | Phase 1 | 29 | Hutchison Medipharma LimitedINDUSTRY | 1 | Jun 16, 2020 | clinicaltrials |
| NCT04417933 | Tumor Electric Fields Treatment System for Glioblastoma | unknown | Early Phase 1 | 5 | Xiangya Hospital of Central South UniversityOTHER | 1 | Jun 11, 2020 | clinicaltrials |
Data updated 24 days agoSource updated Dec 19, 2020source: clinicaltrials